FMP
Nov 15, 2024 12:37 PM - Davit Kirakosyan
Image credit: FMP
Guggenheim analysts reaffirmed a Buy rating and a $23 price target for Cabaletta Bio (NASDAQ:CABA) following the company’s third-quarter results. The analysts highlighted several positive developments that support the company’s progress and growth prospects.
Enrollment for Cabaletta’s clinical trials showed significant acceleration, with 16 patients enrolled across 40 active sites as of November 12, compared to 9 patients as of August 5, 2024. This marks a meaningful step forward in advancing its programs. In 2025, the company plans to engage with the FDA to discuss a potential registrational pathway for its lead candidate, CABA-201.
At the American College of Rheumatology (ACR) meeting, Cabaletta presented data from eight patients across conditions including Myositis, systemic lupus erythematosus (SLE), and systemic sclerosis (SSc). Additionally, initial data from its generalized Myasthenia Gravis (gMG) study are expected in the first half of 2025, further advancing its pipeline.
May 14, 2024 11:41 AM - Sanzhi Kobzhan
A stock's target price, also known as its fair value, is an indication of what a share can cost based on the company’s forecasted financial statements. It is important to know a stock's fair value to find undervalued stocks with great growth potential. Let's consider how investment analysts calculat...
May 24, 2024 9:30 AM - Rajnish Katharotiya
Earnings call transcripts are invaluable resources for investors, analysts, and financial enthusiasts. They provide insights into a company's performance, strategy, and future outlook, making them essential for making informed investment decisions. With Financial Modeling Prep, Earnings Call Transcr...
May 27, 2024 3:30 PM - Rajnish Katharotiya
In the ever-evolving world of technology, certain sectors have consistently demonstrated exceptional growth and innovation. The graphics processing units (GPUs) industry is one such sector, offering investors a golden opportunity for potentially high returns. In this blog, we'll delve into why inves...